Helus Pharma Inc. Common Stock
HELP
60 hedge funds and large institutions have $8.19M invested in Helus Pharma Inc. Common Stock in 2022 Q2 according to their latest regulatory filings, with 15 funds opening new positions, 8 increasing their positions, 10 reducing their positions, and 6 closing their positions.
150% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 6
18% more funds holding
Funds holding: 51 → 60 (+9)
0.44% less ownership
Funds ownership: 9.44% → 9% (-0.44%)
20% less repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 10
35% less capital invested
Capital invested by funds: $12.6M → $8.19M (-$4.37M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AI
AdvisorShares Investments
Bethesda,
Maryland
|
+$89.9K |
| 2 |
BlackRock
New York
|
+$60.1K |
| 3 |
IWP
IAG Wealth Partners
Waukesha,
Wisconsin
|
+$53.2K |
| 4 |
WS
Wedbush Securities
Los Angeles,
California
|
+$45.6K |
| 5 |
MGIA
Moneta Group Investment Advisors
St Louis,
Missouri
|
+$33.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PCC
Perry Creek Capital
New York
|
-$750K |
| 2 |
Jane Street
New York
|
-$61K |
| 3 |
FIA
FNY Investment Advisers
New York
|
-$36.9K |
| 4 |
PCM
Penserra Capital Management
Orinda,
California
|
-$21.1K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$18K |
HELP Hedge Fund Activity: Q2 2022 in Review
60 of the 5,961 institutional investors tracked by Wall St. Rank reported a position in Helus Pharma Inc. Common Stock (HELP) for Q2 2022, worth a combined $8.19M — down 35% from $12.6M a quarter earlier.
Buyers outnumbered sellers: 15 funds opened new HELP positions and 6 closed out — a net gain of 9 holders — while 8 added to existing stakes and 10 trimmed.
The largest buyer was AdvisorShares Investments, adding an estimated $89.9K. The largest seller was Perry Creek Capital, cutting an estimated $750K.
- 60 institutional investors held Helus Pharma Inc. Common Stock (HELP) as of Q2 2022, up from 51 in Q1 2022.
- Funds reported $8.19M of Helus Pharma Inc. Common Stock stock for Q2 2022, down 35% quarter-over-quarter.
- 15 funds opened new Helus Pharma Inc. Common Stock positions in Q2 2022 and 6 closed out, a net change of +9 holders.
- The largest Helus Pharma Inc. Common Stock buyer in Q2 2022 was AdvisorShares Investments, an estimated $89.9K added.
- The largest Helus Pharma Inc. Common Stock seller in Q2 2022 was Perry Creek Capital, an estimated $750K sold.
Based on aggregated 13F filings for Q2 2022.